Shares of CytoDyn Inc. (OTCMKTS:CYDY – Get Free Report) shot up 2.1% during trading on Friday . The stock traded as high as $0.12 and last traded at $0.12. 1,859,693 shares were traded during mid-day trading, a decline of 12% from the average session volume of 2,111,096 shares. The stock had previously closed at $0.12.
CytoDyn Stock Performance
The company has a fifty day moving average of $0.12 and a two-hundred day moving average of $0.14. The company has a market cap of $145.98 million, a PE ratio of -5.95 and a beta of -0.10.
CytoDyn (OTCMKTS:CYDY – Get Free Report) last issued its earnings results on Tuesday, October 15th. The biotechnology company reported $0.02 earnings per share (EPS) for the quarter.
CytoDyn Company Profile
CytoDyn Inc, a clinical-stage biotechnology company, engages in the development of treatments for multiple therapeutic indications. The company is involved in the clinical development of leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19, human immunodeficiency virus (HIV), Metabolic dysfunction-associated steatohepatitis (MASH), and solid tumors in oncology, such as metastatic triple-negative breast cancer.
Further Reading
- Five stocks we like better than CytoDyn
- The 3 Best Blue-Chip Stocks to Buy Now
- Cold Front, Hot Stocks: Diesel Prices Propel Energy Leaders
- 3 REITs to Buy and Hold for the Long Term
- Sustainable and Successful: 3 Climate ETFs Beating the Market
- What is a Secondary Public Offering? What Investors Need to Know
- Quantum Opportunity: Skywater Technology’s Long-Term Potential
Receive News & Ratings for CytoDyn Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CytoDyn and related companies with MarketBeat.com's FREE daily email newsletter.
